Nephrology

This topline look at the KDIGO 2022 updated guideline highlights new recommendations for clinical use of SGLT2i, GLP-1 RA, and nonsteroidal MRA.

Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.

Dr Maruthur, a primary care physician, helped develop the new ADA/EASD consensus report on T2D management and has suggestions.

Dr Maruthur, of Johns Hopkins Medicine, talks about how the concept of "holistic" patient care continues to expand in the management of persons with T2D.

The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.

Nocturnal HTN is a risk factor for cardiovascular disease and stroke. How do you diagnose and treat in your practice? Test your overnight BP IQ.

Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.

Analysis of 224 000 type 2 diabetes patients over 2 decades suggests the need for "revised care pathways" that better reflect the myriad causes of persistent morbidity.

In a study of nearly 100 adults with CKD stages G3b-4 and medical comorbidity, a 12-month exercise program was found safe and improved physical functioning.

The GLP-1 RA given once weekly to T2D patients with hyperglycemia not controlled by diet and exercise lowered HbA1c to ≤6.5% in approximately half the study population.

Chronic kidney disease is underdiagnosed and undertreated across major Western countries, according to findings of the new CaReMe CKD study.

Medicare Advantage plans may cut treatment corners to avoid more costly but more effective and targeted therapy for diabetes patients.

Empagliflozin was associated with a nearly 40% reduced risk of incident renal stone disease vs placebo in a large analysis of data pooled from randomized clinical trials.

Primary care clinicians are critical to screening and caring for CKD. This "In brief" slide show reviews the 2 key lab tests used to diagnose the disease.

ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.

ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.

The USPSTF is rumored to have moved screening for chronic kidney disease to a preventive service it is actively considering and the NFK says, "It's time."

High-level results show the trial met its composite primary endpoint, lowering risk of CV death or worsening disease in patients with HFmrEF/HFpEF.

PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.

The NDA for daprodustat, a novel investigational agent, is based on data from pivotal ASCEND program clinical trials.

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.

ACC 2022: Updated findings further highlight benefit of sotagliflozin treatment in patients with T2D and CKD, regardless of cardiovascular disease presence.

The phase 3 EMPA-KIDNEY clinical trial had just met prespecified criteria for positive efficacy when the study's Independent Data Monitoring Committee recommended the early halt.

Use of continuous glucose monitoring to assess time in target glucose range in T2D patients was evaluated in a systematic literature review covering ~14 000 participants.

The ADA's annual update to its comprehensive evidence-based standards includes new guidance on diabetes screening, first-line therapies, and comorbid NAFLD/NASH.

Finerenone, the nonsteroidal mineralocorticoid receptor antagonist, significantly reduced new-onset HF and improved other HF outcomes in the FIGARO-DKD trial.

The Guideline Toplines slide-show feature offers busy primary care physicians at-a-glance summaries of new and updated clinical guidelines across therapeutic areas.

Finerenone was associated with a 20% lower risk of end-stage kidney disease among patients with T2D and CKD, according to authors of the FIDELITY analysis.

Hypertension, chronic kidney disease, and NAFLD/NASH are frequently first diagnosed in primary care. Try these 10 questions on diagnosis and treatment of all 3.

Finerenone, in patients with mild-to-moderate renal disease and T2D, reduced CV event risk by 13% and risk for a composite renal event by 23%, study authors reported at ESC 2021.